Debt to Equity Ratio Chart

View Debt to Equity Ratio for VYCO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 -0.2253
March 31, 2026 -0.2319
December 31, 2025 -0.2467
September 30, 2025 -0.2574
June 30, 2025 -0.2614
March 31, 2025 -0.2642
December 31, 2024 -0.2866
September 30, 2024 -0.294
June 30, 2024 -0.3008
March 31, 2024 -0.3078
December 31, 2023 -0.3338
September 30, 2023 -0.3504
June 30, 2023 -0.3133
March 31, 2023 -0.3124
December 31, 2022 -0.338
September 30, 2022 -0.3406
June 30, 2022 -0.3482
March 31, 2022 -0.3574
December 31, 2021 -0.3623
September 30, 2021 -0.3975
June 30, 2021 -0.4536
March 31, 2021 -0.445
December 31, 2020 -0.4881
September 30, 2020 -0.5236
June 30, 2020 -0.5027
Date Value
March 31, 2020 -0.5074
December 31, 2019 -0.4333
September 30, 2019 -0.4779
June 30, 2019 -0.5742
March 31, 2019 -0.6387
December 31, 2018 -0.6748
September 30, 2018 -1.286
June 30, 2018 -2.027
March 31, 2018 -1.287
December 31, 2017 3.912
September 30, 2017 0.816
June 30, 2017 0.3711
March 31, 2017 0.4411
December 31, 2016 -25.22
September 30, 2016 1.459
June 30, 2016 0.7559
March 31, 2016 0.3732
December 31, 2015 0.2756
September 30, 2015 0.219
June 30, 2015 0.1606
March 31, 2015 0.1402
December 31, 2014 0.1114
September 30, 2014 0.1029
June 30, 2014 1.794
March 31, 2014 -10.91

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Abbott Laboratories 0.638
AngioDynamics, Inc. 0.0641
Alphatec Holdings, Inc. 52.37
AtriCure, Inc. 0.1437
Baxter International, Inc. 1.427